Dundee Cell Products

Dundee Cell Products (DCP) is a biotechnology and life-sciences research company headquartered in Dundee, Scotland. The company was established in 2006 as a spinout from the School of Life Sciences at the University of Dundee by Dr Paul Ajuh and Professor Angus Lamond. Its business was built around commercializing research capabilities and technologies originating in academic life-sciences research, while maintaining close links with researchers at the University of Dundee. DCP operates across several connected parts of the life-sciences tools and services market. It develops and sells research reagents and laboratory products used in biochemistry, molecular biology, cell biology, and proteomics. It also commercializes products licensed from academic institutions, distributes products from commercial partners, and undertakes contract research for academic groups, pharmaceutical companies, and biotechnology companies. This combination gives the company a role both as a supplier of laboratory materials and as an outsourced research partner. The company’s initial portfolio included antibodies, mammalian cell fractions for precursor messenger RNA-splicing research, and tissue-culture media formulated for stable-isotope labeling by amino acids in cell culture, commonly known as SILAC. Its SILAC-ready media were designed to make quantitative proteomics workflows more accessible to researchers who were not specialists in the technique, while also supporting high-throughput and comparatively unbiased analysis of cellular protein changes. DCP subsequently broadened its portfolio to include cell-culture media for quantitative proteomics, nuclei, nucleoli, mitochondria and other mammalian cell fractions, antibodies, recombinant proteins, fluorescent cell markers, and primary mammalian cells. Its service offering included gene synthesis, DNA cloning, recombinant-protein expression and purification, stable-cell-line development, custom monoclonal and polyclonal antibody generation, and qualitative and quantitative proteomics. Quantitative approaches referenced in the company’s activities included SILAC, tandem mass tags, iTRAQ, isotope-coded affinity tags, and label-free analysis. Research and development activities described for the company included collaborations involving virus–host interactions, cellular proteomes, phosphoproteomics, and transmissible spongiform encephalopathy research. DCP also pursued applications of SILAC-based quantitative proteomics in predictive toxicology, with the aim of generating information that could support earlier assessment of drug toxicity during pharmaceutical discovery and development. The company raised equity investment from angel investors in 2007 and obtained follow-on investment in 2009 from angel investors and the Scottish Co-investment Fund. These investments were intended to support expansion and growth. The available reference material describes growth in the company’s product portfolio and turnover during the period covered, but does not establish its current ownership, financial condition, trading status, or operational scale. DCP’s present status should therefore be treated as unconfirmed.

Dundee Cell Products was founded in 2006 in Dundee as a spinout from the University of Dundee’s School of Life Sciences. The venture was created by Dr Paul Ajuh and Professor Angus Lamond, whose academic research interests helped shape the company’s early commercial portfolio. Rather than operating solely as a conventional laboratory-supplies distributor, DCP was established to transfer research expertise and technologies into products and services for the wider life-sciences community. The company maintained a close relationship with the University of Dundee after its formation. This relationship supported the development and commercialization of research tools associated with molecular biology, cell biology, and proteomics. DCP’s initial products included antibodies, mammalian cell fractions used in precursor messenger RNA-splicing research, and tissue-culture media designed for SILAC-based quantitative proteomics. The founders’ research backgrounds provided a starting point for identifying specialist products that could be useful to academic and industrial scientists. In 2007, DCP secured equity financing from a syndicate of angel investors. A further investment round followed in 2009, involving angel investors and the Scottish Co-investment Fund. The stated purpose of the investment was to finance expansion and support the company’s growth plans. Reference material from the period reports growth in the company’s product portfolio and turnover, although it does not provide independently verifiable current financial figures. DCP expanded beyond its initial products into a broader range of research reagents. Its portfolio came to include SILAC-ready media, nuclei, nucleoli, mitochondria and other mammalian cell fractions, antibodies, recombinant proteins, fluorescent cell markers, and primary mammalian cells. The SILAC media were positioned as a way to simplify quantitative proteomics for non-specialists and for researchers seeking high-throughput approaches to studying changes in cellular proteins. The company also developed a services business. Its listed capabilities included gene synthesis, DNA cloning, recombinant-protein expression and purification, stable-cell-line development, and the custom production of monoclonal and polyclonal antibodies. Proteomics services covered both quantitative and qualitative work, including SILAC, tandem mass tags, iTRAQ, isotope-coded affinity tags, and label-free methods. These services were intended for academic researchers as well as biotechnology and pharmaceutical customers that needed specialist experimental capacity. Research collaborations associated with DCP included projects examining the effects of viral infection on cellular proteomes and the molecular pathways involved in virus–host factor interactions. The company also participated in phosphoproteomics research concerning transmissible spongiform encephalopathies, a group of fatal neurodegenerative diseases that includes bovine spongiform encephalopathy and Creutzfeldt–Jakob disease. Later research and development work focused on applying SILAC quantitative proteomics to predictive toxicology, with the objective of supporting earlier evaluation of potential drug toxicity. The available material identifies John Ivinson as chief executive officer and Angus Lamond as scientific advisor, and notes that Paul Ajuh later moved to Gemini Biosciences. It does not provide sufficient current corporate information to establish whether Dundee Cell Products remains active, has changed ownership, or continues to trade under the same name. Its present status is therefore recorded as unknown.

1. 2009Follow-on investment

   DCP received further investment from angel investors and the Scottish Co-investment Fund to support its growth plans.

   Source
2. 2007Initial angel investment

   The company secured equity funding from a syndicate of angel investors to finance expansion and develop its activities.

   Source
3. 2006Founded as a University of Dundee spinout

   Dundee Cell Products was established as a spinout from the University of Dundee’s School of Life Sciences by Dr Paul Ajuh and Professor Angus Lamond.

   Source

A specialist life-sciences research-tools and contract-research provider connecting academic biotechnology innovation with laboratory, pharmaceutical, and biotechnology customers.

• SILAC-ready mediaCell-culture media

  Tissue-culture media formulated for stable-isotope labeling by amino acids in cell culture. The products were intended to facilitate quantitative proteomics for researchers who were new to SILAC as well as for laboratories applying high-throughput analysis of cellular protein changes.

• Mammalian cell fractionsCell biology reagents

  Prepared mammalian cellular fractions, including nuclei, nucleoli, mitochondria, and other fractions used in molecular and cell biology research. Early applications included precursor messenger RNA-splicing studies and quantitative proteomics workflows.

• Antibodies and recombinant proteinsBioreagents

  Research reagents developed or commercialized for biochemical, molecular-biology, and cell-biology experiments. The broader portfolio included antibodies and recombinant proteins for laboratory investigation and assay development.

• Fluorescent cell markers and primary mammalian cellsCell biology products

  Cell-based research materials intended to support visualization, characterization, and experimentation in mammalian cell biology. The available material identifies these as part of DCP’s expanded product portfolio but does not specify individual product names.

1. Dundee Cell Products